CLEC2B

Across TCGA pan-cancer cohorts, CLEC2B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLEC2B data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLEC2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC2B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC and GBM are the cancer types where CLEC2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.227	0.632	.008	13	view →
GBM	DFS	Tertile	All	0.985	0.397	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLEC2B–PDAC (DFS)

Open the PDAC breakdown →